Invacare 2011 Annual Report Download - page 22

AVAILABLE INFORMATION
The company files Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on
Form 8-K, and any amendments thereto, as well as proxy statements and other documents with the Securities and
Exchange Commission (SEC). The public may read and copy any material that the company files with the SEC at
the SEC’s Public Reference Room located at 100 F Street, NE, Washington D.C. 20549. The public may obtain
information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC
also maintains a website, www.sec.gov, which contains all reports, proxy statements and other information filed
by the company with the SEC.
Additionally, Invacare’s filings with the SEC are available on or through the company’s website,
www.invacare.com, as soon as reasonably practicable after they are filed electronically with, or furnished to, the
SEC. Copies of the company’s filings also can be requested, free of charge, by writing to: Shareholder Relations
Department, Invacare Corporation, One Invacare Way, P.O. Box 4028, Elyria, OH 44036-2125.
FORWARD-LOOKING INFORMATION
This Form 10-K contains forward-looking statements within the meaning of the “Safe Harbor” provisions
of the Private Securities Litigation Reform Act of 1995. Terms such as “will,” “should,” “could,” “plan,”
“intend,” “expect,” “continue,” “forecast,” “believe,” “anticipate” and “seek,” as well as similar comments,
are forward-looking in nature. Because forward-looking statements relate to the future, they are subject to
inherent uncertainties, risks and changes in circumstances that are difficult to predict. Actual results and events
may differ significantly from those expressed or anticipated as a result of risks and uncertainties which include,
but are not limited to, the following: compliance costs, limitations on the production and/or marketing of the
Company’s products or other adverse effects of enforcement actions which could arise from the current, ongoing
FDA investigations and negotiations on a proposed consent decree, and the risk that the Company and the FDA
may not reach agreement on the terms of a consent decree; adverse changes in government and other third-party
payor reimbursement levels and practices (such as, for example, the Medicare national competitive bidding
program covering nine metropolitan areas beginning in 2011 and an additional 91 metropolitan areas beginning
in July 2013), impacts of the 2010 U.S. health care reform legislation (such as, for example, the excise tax
beginning in 2013 on certain medical devices, together with further regulations to be promulgated by the U.S.
Secretary of Treasury, if adopted); extensive government regulation of the Company’s products; legal actions,
regulatory proceedings or governmental investigations; or the Company’s failure to comply with regulatory
requirements or receive regulatory clearance or approval for the Company’s products or operations in the
United States or abroad; product liability claims; the uncertain impact on the Company’s providers, on the
Company’s suppliers and on the demand for the Company’s products resulting from the current global economic
conditions and general volatility in the credit and stock markets; loss of key health care providers; exchange rate
and tax rate fluctuations; inability to design, manufacture, distribute and achieve market acceptance of new
products with higher functionality and lower costs; consolidation of health care providers and the Company’s
competitors; lower cost imports; uncollectible accounts receivable; difficulties in implementing/upgrading
Enterprise Resource Planning systems; risks inherent in managing and operating businesses in many different
foreign jurisdictions; ineffective cost reduction and restructuring efforts; potential product recalls; natural
disasters that lead to supply chain disruptions beyond the Company’s control; possible adverse effects of being
leveraged, which could impact the Company’s ability to raise capital, limit its ability to react to changes in the
economy or the health care industry or expose the Company to interest rate or event of default risks; increased
freight costs; inadequate patents or other intellectual property protection; incorrect assumptions concerning
demographic trends that impact the market for the Company’s products; unanticipated changes in the
Company’s product sales mix; decreased availability or increased costs of materials which could increase the
Company’s costs of producing or acquiring the Company’s products, including possible increases in commodity
costs; the loss of the services of or inability to attract and maintain the Company’s key management and
personnel; inability to acquire strategic acquisition candidates because of limited financing alternatives;
I-16